

Angiogenesis, Kaposi's Sarcoma and Kaposi's Sarcoma-associated Herpesvirus*

Tao KANG^{1,2,3}, Feng-chun Ye³, Shou-jiang gao^{1,3**} and Lin-ding WANG^{1,3**}

(1. Tumor Virology Group, State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China; 2. Graduate School of the Chinese Academy of Sciences, Beijing 100039, China; 3. Tumor Virology Program, Greehey Children's Cancer Research Institute and Department of Pediatrics, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA)

Abstract: Tumor angiogenesis is the uncontrolled growth of blood vessels in tumors, serving to supply nutrients and oxygen, and remove metabolic wastes. Kaposi's sarcoma (KS), a multifocal angioproliferative disorder characterized by spindle cell proliferation, neo-angiogenesis, inflammation, and edema, is associated with infection by Kaposi's sarcoma-associated herpesvirus (KSHV). Recent studies indicate that KSHV infection directly promotes angiogenesis and inflammation through an autocrine and paracrine mechanism by inducing pro-angiogenic and pro-inflammatory cytokines. Many of these cytokines are also expressed in KS lesions, implicating a direct role of KSHV in the pathogenesis of this malignancy. Several KSHV genes are involved in KSHV-induced angiogenesis. These studies have provided insights into the pathogenesis of KS, and identified potential therapeutic targets for this malignancy.

Key words: Angiogenesis; Kaposi's sarcoma (KS); Kaposi's sarcoma-associated herpesvirus (KSHV)

Kaposi's sarcoma (KS) was first described in 1872 by the Hungarian dermatologist Moritz Kaposi. The etiologic factor of KS disease was not established

until 1994 when the team of Chang and Moore discovered Kaposi's sarcoma-associated herpesvirus (KSHV) in a KS tumor from an AIDS patient (12). Since its initial discovery, extensive studies have been performed to confirm the causal link between KSHV and KS. It is now clear that infection by KSHV is necessary for the development of all clinical forms of KS. KSHV is also associated with two other lymphoproliferative diseases including primary effusion lymphoma (PEL) and multicentric Castleman's disease (MCD) (59).

Received: 2008-08-14, Accepted: 2008-09-18

* Foundation items: The Knowledge Innovation Program of the Chinese Academy of Sciences Chinese Academy of Sciences (0702121YJ1); Open Research Fund Program of the State Key Laboratory of Virology of China (2007013); A Type B Outstanding Abroad Young Scientist Award (30328001) from the National Science Foundation of China; and grants from the National Institutes of Health (CA096512, CA124332, CA119889 and DE017333).

** Corresponding author.

Dr. Shou-Jiang Gao: Tel: +1-210-562-9030,

E-mail: gaos@uthscsa.edu;

Dr. Linding Wang: Tel/Fax: +86-27-87197600;

E-mail: wangld@wh.iov.cn

ANGIOGENESIS

The budding of new capillary branches from existing

blood vessels is termed angiogenesis. Under pathological conditions, tumors stimulate angiogenesis to support extra consumption of oxygen and nutrition for their rapid growth (27). Tumor angiogenesis is a complex process involved with the tight interplay of tumor cells, endothelial cells, phagocytes and their secreted factors. Many different proteins such as Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), interleukin-8 (IL-8), matrix metalloproteinases (MMPs), as well as several smaller molecules such as adenosine and prostaglandin E₂ (PGE₂) have been identified as pro-angiogenic factors secreted by tumor cells to mediate angiogenesis. MMPs are expressed in a wide variety of cancers and involved in cancer invasion, metastasis, and angiogenesis (15). MMPs regulate cellular functions and microenvironments by cleaving extracellular matrix proteins, resulting in the escape of endothelial cells from the existing capillary, a key step in the angiogenic cascade.

VEGF and bFGF are important factors for the growth of blood vessels. VEGF is the main driving force behind tumor angiogenesis by inducing the secretion of proteases, and migration and proliferation of endothelial cells (18). By inhibiting apoptosis, VEGF is also a survival factor for endothelial cells.

Angiopoietin 1 (Ang-1) and Angiopoietin 2 (Ang-2) are key players in the angiogenic balance between the quiescence status and activation of the endothelium (35). They share the same receptor, Tie-2. Ang-1 is an agonist of the Tie-2 receptor and stabilizes blood vessels by promoting adhesive interactions between endothelial cells and mural cells. Conversely, Ang-2 is an antagonist of the Tie-2 receptor and induces the detachment of mural cells and destabilizes the existing

blood vessels, a process that is essential for the formation of new blood vessels.

Most tumors are hypoxic because the tumor cell proliferation often exceeds development of new blood vessels. Hypoxia induces the expression of different factors such as hypoxia-inducible factor-1 (HIF-1) or platelet derived growth factor (PDGF) (48). These factors promote neoplastic angiogenesis by inducing specific angiogenic molecules. HIFs are master regulators of both developmental and pathological angiogenesis, composed of an oxygen-sensitive α subunit and a constitutively expressed β subunit (64). HIFs are post-transcriptionally activated by hypoxia as a result of increased protein stability of the α subunits (HIF-1 α and/or HIF-2 α) (64).

KAPOSI'S SARCOMA AND ANGIOGENESIS

KS is a multifocal vascular proliferative disease manifested in four clinic forms: classical KS, endemic (Africa) KS, immunosuppression (transplantation) iatrogenic KS and epidemic (AIDS) KS. Classical form of KS is a rare disease usually restricted to the skin and is predominantly found in elderly males of Mediterranean and Eastern European decent. This form of KS is generally not life-threatening. Endemic KS was described in several Central African countries. It can appear as classical KS, progressing slowly, or in a more deadly form that quickly spreads to tissues below the skin, the bones and lymph system, leading to death within a few years of diagnosis. Immunosuppression KS is observed in transplant patients treated with immunosuppressive agents. AIDS-KS, initially found among homosexual males, is associated with HIV-1 infection. This epidemic KS form usually progresses rapidly. In some HIV-1 endemic areas of

Central Africa, this form of KS is the most frequent cancer, representing about 50% of all diagnosed malignancies (41).

The four clinical forms of KS share a common histology (61). All KS lesions contain the so-called spindle cells, which are the principal proliferating cell, the driving force behind KS histogenesis, named for its dramatically elongated morphology. All KS lesions contain inflammatory cells and slit-like neovascular spaces, which are the features of KS. These new vessels are not intact, and lack of accompanied pericytes or smooth muscle cells, manifesting leakage, which is presumably the cause of edema and hemorrhage observed in KS lesions. KS lesions have aberrant expression of cytokines. Int-2, a pro-angiogenic factor, was found to be expressed in more than half of the KS tumors examined. Using reverse transcription PCR, the expression of int-2 was detected in 21 of 38 (55.2%) fresh KS biopsy specimens (28).

Early stage KS is not a true tumor but a hyperplasia. The progression of KS is linked to the inflammatory and angiogenic process as well as a disturbance of the immune system with a high level of interferon- γ . KS itself starts as a granulation-like tissue rich in inflammatory cells consisting of lymphocytes and monocyte/macrophages. These infiltrating cells produce inflammatory cytokines such as interferon- γ , tumor necrosis factor- α (TNF- α), interleukin-1 β (IL-1 β), interleukin-2 (IL-2), interleukin-6 (IL-6), and IL-8 and oncostatin M (21, 57). These inflammatory cells induce the recruitment of circulating cells into tissues, promote the production of angiogenic factors that mediate angiogenesis and edema, and activate endothelial cells to acquire the phenotype KS spindle cells (3, 4, 19, 20, 52, 72). Altogether these observations support the

concept that early stage KS is a reactive inflammatory-angiogenic process.

KSHV-INDUCED ANGIOGENESIS

KSHV infection directly induces several pro-angiogenic and pro-inflammatory cytokines, including VEGF, Ang-1, Ang-2, bFGF, IL-6, IL-8, GRO- α , TNF- β , and ephrin B2, most of which are expressed in KS lesions (38, 39, 46, 65, 69). The mRNAs of both Ang-1 and Ang-2 have been detected at higher levels in KS tumors than in the adjacent normal tissues. Ang-2 protein was highly expressed in KS tumors and that KSHV infection of primary human umbilical vein endothelial cells (HUVEC) induced Ang-2, which was required for KSHV-induced paracrine-dependent angiogenesis *in vivo* (71). The induction of Ang-2 by KSHV is mediated by ERK, JNK and p38 mitogen-activated protein kinase (MAPK) pathways (71). A number of MMPs, including MMP-1, -2, -3, -9, and -19, have been detected in KS tumor cells, implicating their roles in the pathogenesis of these tumors. KSHV infection of HUVEC enhances cell invasiveness by inducing the expression of MMP-1, -2, and -9 (49). KSHV infection also induces sustained levels of VEGF-A and VEGF-C early during *in vitro* infection of human microvascular dermal endothelial cells (DMVEC) (58). Angiogenesis induced by PEL cells is dependent on VEGF and VEGF receptors (26). Higher levels of serum VEGF were detected in HIV-1 infected persons with KS compared with HIV-1 infected persons without KS (68). KSHV infection of DMVEC induces mRNA of HIF1 α and HIF2 α (11). Consistent with the *in vitro* results, KS lesions express elevated levels of HIF1 α and HIF2 α proteins (11). KSHV infection of DMVEC also induces the

expression of cyclooxygenase-2 (COX-2) and heme oxygenase-1, both of which play important roles in angiogenesis (40, 46).

In a SCID mouse model with human skin grafts, VEGF was shown to be essential for the inoculated early stage KS cells to grow into KS-like tumors (54). Transfection of mouse bone marrow endothelial-lineage cells with the KSHV recombinant virus BAC36 led to cellular transformation and induced KS-like tumors in mice (45). The KSHV-transformed cells mECK36 expresses most KSHV genes and are angiogenic. In nude mice, mECK36 cells form vascularized spindle cell sarcomas that are LANA+/podosplanin+, overexpressed VEGF and angiopoietin ligands and receptors, and displayed KSHV and host transcripts reminiscent of KS (45). siRNA suppression of KSHV vGPCR, a pro-angiogenic gene upregulated in mECK36 tumors, led to the inhibition of angiogenesis and tumorigenicity.

REGULATION OF ANGIOGENESIS BY KSHV-ENCODED GENES

ORF-K1

ORF-K1 encodes a small transmembrane immunoglobulin-like glycoprotein, which possesses a cytoplasmic immunoreceptor tyrosine activation motif (ITAM) similar to that of the B cell receptor (BCR) (25). This motif was shown to be sufficient for inducing cellular tyrosine phosphorylation (34). The phosphorylation of the ITAM domain allows subsequent binding of SH2 proteins Syk, Vav and phosphoinositide 3-kinase (PI3K) (31). K1 activates the transcription factor NFAT in KSHV negative B-cells. It also activates the PI3K/Akt pathway by enhancing the phosphorylation of the p85 subunit of

PI3K and the kinase Akt in B cells (34, 62). K1 also activates the transcription factor AP-1 and NF- κ B in reporter assays (53). In KS cells, K1 is able to induce the secretion of inflammatory cytokines such as IL-6 and IL-12 (53). Full-length K1 downregulates the expression of the BCR complex at the cell surface of Bjab cells. This could potentially inhibit B-cell activation and allow a long-term survival advantage for KSHV-infected cells (33).

K1 can induce the expression and secretion of VEGF in epithelial and endothelial cells (67). It induces the expression of MMP-9 in endothelial cells (67). The SH2-binding motifs in the cytoplasmic tail are necessary for VEGF secretion and MMP-9 induction. These results indicate that K1 signaling may contribute to KSHV-associated pathogenesis through a paracrine mechanism by promoting the secretion of VEGF and MMP-9 into the surrounding matrix.

ORF-K15

ORF-K15 gene is located at the most right side of the viral genome, and has two distinct isoforms. The M and P (for “minor” and “predominant”) forms of K15 are 67% divergent. The more common variant, K15-P, is considered to be the original K15 gene, whereas the other, K15-M, is thought to represent the result of a recombination event with a related rhadinovirus (29). K15 is able to interact with TRAFs (tumor necrosis factor receptor-associated factor) and Src kinases, and activates AP-1, NF- κ B, and JNK and ERK MAPK pathways (6, 66). The down-stream target genes of K15 signaling are investigated using DNA oligonucleotide microarrays (7). K15 is shown to be able to induce the expression of multiple cytokines and chemokines, including IL-8, IL-6, CCL20, CCL2, CXCL3, and IL-1 α/β , as well as Dscr1

and Cox-2 (7).

vGPCR

vGPCR, encoded by ORF74, is a 7-transmembrane, IL-8 receptor homolog that constitutively engages pathways downstream of multiple G protein subunits in a phospholipase C and PI3K-dependent manner. The pathways engaged by vGPCR include protein kinase C, protein kinase B, Akt, NF- κ B, and MAPKs, leading to increased transcriptional activity of their nuclear targets, stimulation of cellular proliferation, promotion of cell survival, transformation, tumorigenicity, and induction of VEGF-mediated switch to an angiogenic phenotype (16). Microarray experiments have shown that IL-6 and GRO α are highly induced in endothelial cells which stably express vGPCR (47). Cells expressing vGPCR secrete increased levels of autocrine and paracrine cytokines and growth factors (IL- β , TNF- β , IL-6, IL-8, granulocytemacrophage colony-stimulating factor, VEGF, bFGF, and MCP-1), and produce conditioned medium that is chemotactic (16). In transgenic mice, vGPCR induces multifocal, angioproliferative, KS-like lesions (70). vGPCR expression in human pulmonary arterial endothelial cells (HPAEC) selectively activated MMP-2, a pivotal matrix modulating enzyme during angiogenesis. vGPCR induces MMP-2 activation in HPAECs through regulation of MT1-MMP and TMP-2 expression (55). vGPCR also induces Ang-2 expression in lymphatic endothelial cells in a paracrine manner through the ERK MAPK pathway (63). Thus, vGPCR is a viral oncogene that exploits cellular signaling pathways to induce cellular transformation and angiogenesis.

vIL-6

vIL-6 encoded by ORF-K2 is structurally homologous to human and murine IL-6. vIL-6 triggers multiple cellular pathways to induce cell proliferation and extrahepatic acute-phase responses through engagement of the gp130 coreceptor independently of the IL-6 (gp80) receptor. vIL-6, but not human IL-6, protects PEL cells and heterologous cells from the antiviral, cytostatic effects of interferon- α , which down-regulates the surface expression of gp80 but not gp130 (13). vIL-6 induces endogenous human IL-6 secretion in various cell lines (MT-4, THP-1, U937, Raji, and CESS) and in patients with MCD (43). vIL-6 supports the growth of IL-6-dependent cell lines, and is an autocrine growth factor for PEL cells (22, 43).

vIL-6-expressing NIH3T3 cells gives rise to tumors in nude mice more rapidly than control cells, and vIL-6-positive tumors are more vascularized than controls (1). VEGF was detected at higher levels in the culture supernatant of vIL-6-expressing cells compared to controls, and immunohistochemical staining detected VEGF in spleen, lymph nodes, and tumor tissues from mice bearing vIL-6-producing tumors but not in mice bearing the control tumors. vIL-6 also up-regulates Ang-2 expression in lymphatic endothelial cells in a paracrine manner through the MAPK pathway (63). Thus, vIL-6 is a multifunctional cytokine that promotes hematopoiesis, plasmacytosis, and angiogenesis, and might play an important role in the pathogenesis of KSHV-associated disorders.

LANA

LANA (latent nuclear antigen) encoded by ORF73 is expressed in all latently infected cells in KS tumors. It is considered as an oncogenic protein because it inhibits the p53 and pRb tumor suppressor pathways,

and transforms primary rat embryo fibroblasts in cooperation with the cellular oncogene *H-ras* (23, 50). LANA interacts with GSK-3 β , an important modulator of the Wnt signaling pathway, leading to the accumulation of the β -catenin and subsequent upregulation of Tcf/Lef-regulated genes (24). LANA represses the reactivation and transcriptional activator (RTA), which is critical for the virus switch from latency to lytic reactivation, to control viral latency (32). LANA is essential for episome persistence by its critical role in episome replication and partitioning into daughter cells (2).

LANA directly associates with HIF-1 α in transiently transfected 293T cells as well as in PEL cell lines during hypoxia. LANA regulates the hypoxia pathway by enhancing the transcriptional activities of HIF-1 α and upregulating its mRNA level (8). Additional studies indicate that LANA targets the HIF-1 α suppressors von Hippel-Lindau (VHL) protein and p53 for degradation via its suppressor of cytokine signaling-box motif by recruiting the E3 ubiquitin complex (10). LANA is important for HIF-1 α nuclear accumulation in normoxic conditions in KSHV latently infected PEL cells, as well as HEK293 cells infected by KSHV (9). Therefore, LANA can function not only as an inhibitor of HIF-1 α suppressor proteins but can also induce nuclear accumulation of HIF-1 α during KSHV latent infection.

vIRF3

vIRF3 (viral interferon regulatory factor 3), also called LANA2, is encoded by ORF-K10.5. vIRF3 is exclusively detected in KSHV-infected B cells (37, 51). vIRF3 is most closely related to the cellular IRF4 and vIRF2, it functions as a dominant negative mutant

of both IRF3 and IRF7, and inhibits virus mediated transcriptional activity of the interferon- α promoter, and thus blocks type I interferon signaling (37). vIRF3 is also able to inactivate the p53-mediated apoptosis and transcriptional activation (51) as well as apoptosis induced by activation of the serine/threonine kinase PKR (17). vIRF3 is able to bind to 14-3-3 proteins and the transcriptional factor FOXO3a. When 14-3-3 proteins are overexpressed, vIRF3 inhibits the transcriptional activity of FOXO3a and blocks the G2/M arrest (44). Recently, vIRF3 has been shown to interact with HIF-1 α leading to the HIF-1 α stabilization and transcriptional activation of VEGF (56). The central domain of vIRF3, containing double α -helix motifs, is sufficient for the binding to HIF-1 α and blocking its degradation in normoxic conditions. These findings suggest that vIRF3 may have a role in KSHV-mediated oncogenesis in hematopoietic tissues.

vCCL-1, vCCL-2, and vCCL-3

vCCL-1, vCCL-2 and vCCL-3 are encoded by KSHV ORF-K6, -K4 and -K4.1 respectively. vCCL-1 binds to a broad range of chemokine receptors including CCR1, CCR2, CCR5, CXCR4, and CX3CR1 (30). It may function as a competitive antagonist with the host chemokines. vCCL-1 blocked the chemoattractive properties of host CC and CXC chemokines (5, 14, 30, 42). vCCL-1 suppressed the host inflammatory response and decreased the infiltration of inflammatory leukocytes in a rat model (14). vCCL-1 and vCCL-2 are able to bind to CCR-8, and vCCL-1 induces the secretion of VEGF-A in PEL cells (36). Both vCCL-1 and vCCL-2 are able to block dexamethasone-induced apoptosis in PEL cells (36). vCCL-3 binds to CCR-8 and CCR-4, and has been

shown to be a selective chemoattractant for the Th2 cells (60).

All three vCCLs are able to induce angiogenesis in the chorioalantonic membranes of chicken eggs, suggesting that they may act synergistically with host factors such as VEGF, bFGF, and IL-6 to promote the abnormal angiogenesis in KS lesions (5).

CONCLUSION

KS tumor is a highly disseminated angiogenic tumor of proliferative endothelial cells, and the KS progression is linked to the inflammatory and angiogenic process. Recent studies have shown that KSHV infection induces several angiogenic and inflammatory cytokines, which directly contributes to the tumor neo-angiogenesis process, and the pathogenesis of the malignancy. A number of genes encoded by KSHV have been shown to promote angiogenesis. Nevertheless, the mechanism of KSHV-induced angiogenesis is very complex; additional research works are needed to further delineate the molecular basis of KSHV-mediated angiogenesis in the KS tumor.

References

1. **Aoki Y, Jaffe E S, Chang Y, et al.** 1999. Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. *Blood*, 93: 4034-4043.
2. **Ballestas M E, Chatis P A, Kaye K M.** 1999. Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. *Science*, 284: 641-644.
3. **Barillari G, Gendelman R, Gallo R C, et al.** 1993. The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi's sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence. *Proc Natl Acad Sci USA*, 90: 7941-7945.
4. **Barillari G, Sgadari C, Palladino C, et al.** 1999. Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi's sarcoma via induction of basic fibroblast growth factor and the alpha v beta 3 integrin. *J Immunol*, 163: 1929-1935.
5. **Boshoff C, Endo Y, Collins P D, et al.** 1997. Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. *Science*, 278: 290-294.
6. **Brinkmann M M, Glenn M, Rainbow L, et al.** 2003. Activation of mitogen-activated protein kinase and NF-kappaB pathways by a Kaposi's sarcoma-associated herpesvirus K15 membrane protein. *J Virol*, 77: 9346-9358.
7. **Brinkmann M M, Pietrek M, Dittrich-Breiholz O, et al.** 2007. Modulation of host gene expression by the K15 protein of Kaposi's sarcoma-associated herpesvirus. *J Virol*, 81: 42-58.
8. **Cai Q, Lan K, Verma S C, et al.** 2006. Kaposi's sarcoma-associated herpesvirus latent protein LANA interacts with HIF-1 alpha to upregulate RTA expression during hypoxia: Latency control under low oxygen conditions. *J Virol*, 80: 7965-7975.
9. **Cai Q, Murakami M, Si H, et al.** 2007. A potential alpha-helix motif in the amino terminus of LANA encoded by Kaposi's sarcoma-associated herpesvirus is critical for nuclear accumulation of HIF-1alpha in normoxia. *J Virol*, 81: 10413-10423.
10. **Cai Q L, Knight J S, Verma S C, et al.** 2006. EC5S ubiquitin complex is recruited by KSHV latent antigen LANA for degradation of the VHL and p53 tumor suppressors. *PLoS Pathog*, 2: e116.
11. **Carroll P A, Kenerson H L, Yeung R S, et al.** 2006. Latent Kaposi's sarcoma-associated herpesvirus infection of endothelial cells activates hypoxia-induced factors. *J Virol*, 80: 10802-10812.
12. **Chang Y, Cesarman E, Pessin M S, et al.** 1994. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. *Science*, 266: 1865-1869.
13. **Chatterjee M, Osborne J, Bestetti G, et al.** 2002. Viral IL-6-induced cell proliferation and immune evasion of interferon activity. *Science*, 298: 1432-1435.
14. **Chen S, Bacon K B, Li L, et al.** 1998. *In vivo* inhibition

- of CC and CX3C chemokine-induced leukocyte infiltration and attenuation of glomerulonephritis in Wistar-Kyoto (WKY) rats by vMIP-II. **J Exp Med**, 188: 193-198.
15. **Deryugina E I, Quigley J P.** 2006. Matrix metalloproteinases and tumor metastasis. **Cancer Metastasis Rev**, 25: 9-34.
 16. **Dourmishev L A, Dourmishev A L, Palmeri D, et al.** 2003. Molecular genetics of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis. **Microbiol Mol Biol Rev**, 67: 175-212.
 17. **Esteban M, Garcia M A, Domingo-Gil E, et al.** 2003. The latency protein LANA2 from Kaposi's sarcoma-associated herpesvirus inhibits apoptosis induced by dsRNA-activated protein kinase but not RNase L activation. **J Gen Virol**, 84: 1463-1470.
 18. **Ferrara N, Gerber H P, LeCouter J.** 2003. The biology of VEGF and its receptors. **Nat Med**, 9: 669-676.
 19. **Fiorelli V, Barillari G, Toschi E, et al.** 1999. IFN-gamma induces endothelial cells to proliferate and to invade the extracellular matrix in response to the HIV-1 Tat protein: implications for AIDS-Kaposi's sarcoma pathogenesis. **J Immunol**, 162: 1165-1170.
 20. **Fiorelli V, Gendelman R, Samaniego F, et al.** 1995. Cytokines from activated T cells induce normal endothelial cells to acquire the phenotypic and functional features of AIDS-Kaposi's sarcoma spindle cells. **J Clin Invest**, 95: 1723-1734.
 21. **Fiorelli V, Gendelman R, Sirianni M C, et al.** 1998. gamma-Interferon produced by CD8⁺ T cells infiltrating Kaposi's sarcoma induces spindle cells with angiogenic phenotype and synergy with human immunodeficiency virus-1 Tat protein: an immune response to human herpesvirus-8 infection? **Blood**, 91: 956-967.
 22. **Foussat A, Wijdenes J, Bouchet L, et al.** 1999. Human interleukin-6 is *in vivo* an autocrine growth factor for human herpesvirus-8-infected malignant B lymphocytes. **Eur Cytokine Netw**, 10: 501-508.
 23. **Friborg J Jr, Kong W, Hottiger M O, et al.** 1999. p53 inhibition by the LANA protein of KSHV protects against cell death. **Nature**, 402: 889-894.
 24. **Fujimuro M, Wu F Y, ApRhys C, et al.** 2003. A novel viral mechanism for dysregulation of beta-catenin in Kaposi's sarcoma-associated herpesvirus latency. **Nat Med**, 9: 300-306.
 25. **Gold M R.** 2002. To make antibodies or not: signaling by the B-cell antigen receptor. **Trends Pharmacol Sci**, 23: 316-324.
 26. **Haddad L, El Hajj H, Abou-Merhi R, et al.** 2008. KSHV-transformed primary effusion lymphoma cells induce a VEGF-dependent angiogenesis and establish functional gap junctions with endothelial cells. **Leukemia**, 22: 826-834.
 27. **Hanahan D, Folkman J.** 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. **Cell**, 86: 353-364.
 28. **Huang Y Q, Li J J, Moscatelli D, et al.** 1993. Expression of int-2 oncogene in Kaposi's sarcoma lesions. **J Clin Invest**, 91: 1191-1197.
 29. **Kakoola D N, Sheldon J, Byabazaire N, et al.** 2001. Recombination in human herpesvirus-8 strains from Uganda and evolution of the K15 gene. **J Gen Virol**, 82: 2393-2404.
 30. **Kledal T N, Rosenkilde M M, Coulin F, et al.** 1997. A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. **Science**, 277: 1656-1659.
 31. **Lagunoff M, Majeti R, Weiss A, et al.** 1999. Deregulated signal transduction by the K1 gene product of Kaposi's sarcoma-associated herpesvirus. **Proc Natl Acad Sci USA**, 96: 5704-5709.
 32. **Lan K, Koppers D A, Verma S C, et al.** 2004. Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen inhibits lytic replication by targeting Rta: a potential mechanism for virus-mediated control of latency. **J Virol**, 78: 6585-6594.
 33. **Lee B S, Alvarez X, Ishido S, et al.** 2000. Inhibition of intracellular transport of B cell antigen receptor complexes by Kaposi's sarcoma-associated herpesvirus K1. **J Exp Med**, 192: 11-21.
 34. **Lee H, Guo J, Li M, et al.** 1998. Identification of an immunoreceptor tyrosine-based activation motif of K1 transforming protein of Kaposi's sarcoma-associated herpesvirus. **Mol Cell Biol**, 18: 5219-5228.
 35. **Lemieux C, Maliba R, Favier J, et al.** 2005. Angio-

- poietins can directly activate endothelial cells and neutrophils to promote proinflammatory responses. **Blood**, 105: 1523-1530.
36. Liu C, Okruzhnov Y, Li H, *et al.* 2001. Human herpesvirus 8 (HHV-8)-encoded cytokines induce expression of and autocrine signaling by vascular endothelial growth factor (VEGF) in HHV-8-infected primary-effusion lymphoma cell lines and mediate VEGF-independent antiapoptotic effects. **J Virol**, 75: 10933-10940.
 37. Lubyova B, Pitha P M. 2000. Characterization of a novel human herpesvirus 8-encoded protein, vIRF-3, that shows homology to viral and cellular interferon regulatory factors. **J Virol**, 74: 8194-8201.
 38. Masood R, Cesarman E, Smith D L, *et al.* 2002. Human herpesvirus-8-transformed endothelial cells have functionally activated vascular endothelial growth factor/vascular endothelial growth factor receptor. **Am J Pathol**, 160: 23-29.
 39. Masood R, Xia G, Smith D L, *et al.* 2005. Ephrin B2 expression in Kaposi sarcoma is induced by human herpesvirus type 8: phenotype switch from venous to arterial endothelium. **Blood**, 105: 1310-1318.
 40. McAllister S C, Hansen S G, Ruhl R A, *et al.* 2004. Kaposi sarcoma-associated herpesvirus (KSHV) induces heme oxygenase-1 expression and activity in KSHV-infected endothelial cells. **Blood**, 103: 3465-3473.
 41. Mitsuyasu R T. 1988. AIDS-related Kaposi's sarcoma: a review of its pathogenesis and treatment. **Blood Rev**, 2: 222-231.
 42. Moore P S, Boshoff C, Weiss R A, *et al.* 1996. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. **Science**, 274: 1739-1744.
 43. Mori Y, Nishimoto N, Ohno M, *et al.* 2000. Human herpesvirus 8-encoded interleukin-6 homologue (viral IL-6) induces endogenous human IL-6 secretion. **J Med Virol**, 61: 332-335.
 44. Munoz-Fontela C, Marcos-Villar L, Gallego P, *et al.* 2007. Latent protein LANA2 from Kaposi's sarcoma-associated herpesvirus interacts with 14-3-3 proteins and inhibits FOXO3a transcription factor. **J Virol**, 81: 1511-1516.
 45. Mutlu A D, Cavallin L E, Vincent L, *et al.* 2007. In vivo-restricted and reversible malignancy induced by human herpesvirus-8 KSHV: a cell and animal model of virally induced Kaposi's sarcoma. **Cancer Cell**, 11: 245-258.
 46. Naranatt P P, Krishnan H H, Svojanovsky S R, *et al.* 2004. Host gene induction and transcriptional reprogramming in Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8)-infected endothelial, fibroblast, and B cells: insights into modulation events early during infection. **Cancer Res**, 64: 72-84.
 47. Polson A G, Wang D, DeRisi J, *et al.* 2002. Modulation of host gene expression by the constitutively active G protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus. **Cancer Res**, 62: 4525-4530.
 48. Pugh C W, and Ratcliffe P J. 2003. Regulation of angiogenesis by hypoxia: role of the HIF system. **Nat Med**, 9: 677-684.
 49. Qian L W, Xie J, Ye F, *et al.* 2007. Kaposi's sarcoma-associated herpesvirus infection promotes invasion of primary human umbilical vein endothelial cells by inducing matrix metalloproteinases. **J Virol**, 81: 7001-7010.
 50. Radkov S A, Kellam P, Boshoff C. 2000. The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. **Nat Med**, 6: 1121-1127.
 51. Rivas C, Thlick A E, Parravicini C, *et al.* 2001. Kaposi's sarcoma-associated herpesvirus LANA2 is a B-cell-specific latent viral protein that inhibits p53. **J Virol**, 75: 429-438.
 52. Samaniego F, Markham P D, Gendelman R, *et al.* 1998. Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi's sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development. **Am J Pathol**, 152: 1433-1443.
 53. Samaniego F, Pati S, Karp J E, *et al.* 2001. Human herpesvirus 8 K1-associated nuclear factor-kappa B-dependent promoter activity: role in Kaposi's sarcoma inflammation? **J Natl Cancer Inst Monogr**, 28:15-23.
 54. Samaniego F, Young D, Grimes C, *et al.* 2002. Vascular endothelial growth factor and Kaposi's sarcoma cells in human skin grafts. **Cell Growth Differ**, 13: 387-395.
 55. Shan B, Morris C A, Zhuo Y, *et al.* 2007. Activation of

- proMMP-2 and Src by HHV8 vGPCR in human pulmonary arterial endothelial cells. **J Mol Cell Cardiol**, 42: 517-525.
56. **Shin Y C, Joo C H, Gack M U, et al.** 2008. Kaposi's sarcoma-associated herpesvirus viral IFN regulatory factor 3 stabilizes hypoxia-inducible factor-1 alpha to induce vascular endothelial growth factor expression. **Cancer Res**, 68: 1751-1759.
57. **Sirianni M C, Vincenzi L, Fiorelli V, et al.** 1998. gamma-Interferon production in peripheral blood mononuclear cells and tumor infiltrating lymphocytes from Kaposi's sarcoma patients: correlation with the presence of human herpesvirus-8 in peripheral blood mononuclear cells and lesional macrophages. **Blood**, 91: 968-976.
58. **Sivakumar R, Sharma-Walia N, Raghu H, et al.** 2008. Kaposi's sarcoma-associated herpesvirus induces sustained levels of vascular endothelial growth factors A and C early during *in vitro* infection of human microvascular dermal endothelial cells: biological implications. **J Virol**, 82: 1759-1776.
59. **Soulier J, Grollet L, Oksenhendler E, et al.** 1995. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castlemans disease. **Blood**, 86: 1276-1280.
60. **Stine J T, Wood C, Hill M, et al.** 2000. KSHV-encoded CC chemokine vMIP-III is a CCR4 agonist, stimulates angiogenesis, and selectively chemoattracts TH2 cells. **Blood**, 95: 1151-1157.
61. **Tappero J W, Conant M A, Wolfe S F, et al.** 1993. Kaposi's sarcoma. Epidemiology, pathogenesis, histology, clinical spectrum, staging criteria and therapy. **J Am Acad Dermatol**, 28: 371-395.
62. **Tomlinson C C, Damania B.** 2004. The K1 protein of Kaposi's sarcoma-associated herpesvirus activates the Akt signaling pathway. **J Virol**, 78: 1918-1927.
63. **Vart R J, Nikitenko L L, Lagos D, et al.** 2007. Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6 and G-protein-coupled receptor regulate angiopoietin-2 expression in lymphatic endothelial cells. **Cancer Res**, 67: 4042-4051.
64. **Wang G L, Jiang B H, Rue E A, et al.** 1995. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O₂ tension. **Proc Natl Acad Sci USA**, 92: 5510-5514.
65. **Wang H W, Trotter M W, Lagos D, et al.** 2004. Kaposi's sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. **Nat Genet**, 36: 687-693.
66. **Wang L, Brinkmann M M, Pietrek M, et al.** 2007. Functional characterization of the M-type K15-encoded membrane protein of Kaposi's sarcoma-associated herpesvirus. **J Gen Virol**, 88: 1698-1707.
67. **Wang L, Wakisaka N, Tomlinson C C, et al.** 2004. The Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) K1 protein induces expression of angiogenic and invasion factors. **Cancer Res**, 64: 2774-2781.
68. **Weindel K, Marme D, Weich H A.** 1992. AIDS-associated Kaposi's sarcoma cells in culture express vascular endothelial growth factor. **Biochem Biophys Res Commun**, 183: 1167-1174.
69. **Xie J, Pan H, Yoo S, et al.** 2005. Kaposi's sarcoma-associated herpesvirus induction of AP-1 and interleukin 6 during primary infection mediated by multiple mitogen-activated protein kinase pathways. **J Virol**, 79: 15027-15037.
70. **Yang T Y, Chen S C, Leach M W, et al.** 2000. Transgenic expression of the chemokine receptor encoded by human herpesvirus 8 induces an angioproliferative disease resembling Kaposi's sarcoma. **J Exp Med**, 191: 445-454.
71. **Ye F C, Blackbourn D J, Mengel M, et al.** 2007. Kaposi's sarcoma-associated herpesvirus promotes angiogenesis by inducing angiopoietin-2 expression via AP-1 and Ets1. **J Virol**, 81: 3980-3991.
72. **Zietz C, Hotz B, Sturzl M, et al.** 1996. Aortic endothelium in HIV-1 infection: chronic injury, activation, and increased leukocyte adherence. **Am J Pathol**, 149: 1887-1898.